Means of controlling infection persistence of helicobacter pylori
AssigneeOndek Pty. Ltd.
InventorsMohammed Benghezal, Tobias Schoep, Alma Fulurija, Douglas E. Berg, Barry J. Marshall
Life of this patent
Estimating the term…
Abstract
The present invention relates to a means of controlling infection persistence of Helicobacter pylori (H. pylori). In particular, the present invention relates to an isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori which is unable to establish or maintain a persistent infection.
Claims22
1-21. (canceled)
An isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori that is unable to establish or maintain a persistent infection.
A method of controlling the ability of Helicobacter pylori to establish a persistent infection, the method comprising altering the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 to produce a modified UreB subunit of urease, wherein said urease retains de-acidification function, but said Helicobacter pylori is unable to establish or maintain a persistent infection.
A method of vaccinating an mammal against a Helicobacter pylori infection, the method comprising administering to said mammal an isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori that is unable to establish or maintain a persistent infection.
An immunogenic composition for use in vaccinating a mammal, the composition comprising an isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori that is unable to establish or maintain a persistent infection and a pharmaceutically acceptable carrier.
A peptide vaccine consisting essentially of amino acid 529 to amino acid 555 of SEQ ID NO:1 and a pharmaceutical carrier.
Dependencies are inferred from the claim text.